CoChat

Patología vascular: ¿causa o efecto en la enfermedad de Alzheimer?

Open access
Rius-Pérez, S., Tormos, A.M., Pérez, S., Taléns-Visconti, R. · 2018 · Neurología
Cited by 70

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Resumen Introducción La enfermedad de Alzheimer (EA) es la principal enfermedad neurodegenerativa cortical. Su incidencia aumenta con la edad, lo que provoca importantes problemas médicos, sociales y económicos, especialmente en países con población envejecida. Objetivo El objetivo de esta revisión es poner de manifiesto las evidencias que existen sobre el modo en que la disfunción vascular puede contribuir al deterioro cognitivo en la EA, así como las posibilidades terapéuticas que de ello podrían derivarse. Desarrollo La hipótesis vascular ha surgido como alternativa a la hipótesis de la cascada amiloide como explicación de la fisiopatología de la EA. Esta hipótesis sitúa en los vasos sanguíneos el origen de una serie de estímulos patogénicos que llevarían a la lesión neuronal y la demencia. La destrucción de la organización de la barrera hematoencefálica, la disminución del flujo sanguíneo cerebral y el establecimiento de un contexto inflamatorio serían responsables de un consecuente daño neuronal a causa de favorecer la agregación del péptido β-amiloide en el cerebro. Las vías que relacionan la disfunción vascular con la neurodegeneración han proporcionado nuevos enfoques terapéuticos y dianas farmacológicas con las que avanzar en la búsqueda de tratamientos para la EA. Conclusiones Resulta difícil determinar si el componente vascular de la EA es la causa o el efecto de la enfermedad, pero no cabe duda de que la enfermedad vascular tiene una relación importante con la EA. Es probable que la disfunción vascular actúe sinérgicamente con los cambios neurodegenerativos en un ciclo que agrava el deterioro cognitivo propio de la EA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nrl.2015.07.010

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 45

  1. Ferri, 2005, Global prevalence of dementia: A Delphi consensus study, Lancet., 366, 2112, 10.1016/S0140-6736(05)67889-0 · DOI · Paper page
  2. Gascon-Bayarri, 2007, Prevalence of dementia subtypes in el Prat de Llobregat, Catalonia, Spain: the PRATICON study, Neuroepidemiology., 28, 224, 10.1159/000108597 · DOI · Paper page
  3. Maurer, 1997, Auguste D and Alzheimer's disease, Lancet., 349, 1546, 10.1016/S0140-6736(96)10203-8 · DOI · Paper page
  4. Glenner, 1984, Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun., 120, 885, 10.1016/S0006-291X(84)80190-4 · DOI · Paper page
  5. Goldgaber, 1987, Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease, Science., 235, 877, 10.1126/science.3810169 · DOI · Paper page
  6. Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature., 349, 704, 10.1038/349704a0 · DOI · Paper page
  7. Hardy, 1992, Alzheimer's disease: The amyloid cascade hypothesis, Science., 256, 184, 10.1126/science.1566067 · DOI · Paper page
  8. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science., 297, 353, 10.1126/science.1072994 · DOI · Paper page
  9. Vassar, 1999, Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE, Science., 286, 735, 10.1126/science.286.5440.735 · DOI · Paper page
  10. Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease, Nature., 375, 754, 10.1038/375754a0 · DOI · Paper page
  11. Wolfe, 1999, Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity, Nature., 398, 513, 10.1038/19077 · DOI · Paper page
  12. Bergmans, 2010, Gamma-secretases. From cell biology to therapeutic strategies, Lancet Neurol., 9, 215, 10.1016/S1474-4422(09)70332-1 · DOI · Paper page
  13. Alonso Vilatela, 2012, Genetics of Alzheimer's disease, Arch Med Res., 43, 622, 10.1016/j.arcmed.2012.10.017 · DOI
  14. Grundke-Iqbal, 1986, Microtubule-associated protein tau. A component of Alzheimer paired helical filaments, J Biol Chem., 261, 6084, 10.1016/S0021-9258(17)38495-8 · DOI · Paper page
  15. De la Torre, 1993, Can disturbed brain microcirculation cause Alzheimer's disease?, Neurol Res., 15, 146, 10.1080/01616412.1993.11740127 · DOI · Paper page
  16. Gentleman, 1993, Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury, Neurosci Lett., 160, 139, 10.1016/0304-3940(93)90398-5 · DOI · Paper page
  17. Xu, 2011, Midlife overweight and obesity increase late-life dementia risk: A population-based twin study, Neurology., 76, 1568, 10.1212/WNL.0b013e3182190d09 · DOI · Paper page
  18. Domínguez, 2014, Enfermedad de Alzheimer y deterioro cognitivo asociado a la diabetes mellitus de tipo 2: relaciones e hipótesis, Neurologia., 29, 567, 10.1016/j.nrl.2013.05.006 · DOI
  19. Kopf, 2009, Risk of incident Alzheimer's disease in diabetic patients: A systematic review of prospective trials, J Alzheimers Dis., 16, 677, 10.3233/JAD-2009-1011 · DOI · Paper page
  20. Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study, Lancet., 349, 151, 10.1016/S0140-6736(96)09328-2 · DOI · Paper page
  21. Mooradian, 1997, GLUT-1 expression in the cerebra of patients with Alzheimer's disease, Neurobiol Aging., 18, 469, 10.1016/S0197-4580(97)00111-5 · DOI · Paper page
  22. Sagare, 2012, Low-density lipoprotein receptor-related protein 1: A physiological Aβ homeostatic mechanism with multiple therapeutic opportunities, Pharmacol Ther., 136, 94, 10.1016/j.pharmthera.2012.07.008 · DOI · Paper page
  23. Owen, 2010, Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Aβ accumulation in AD brain, Free Radic Biol Med., 49, 1798, 10.1016/j.freeradbiomed.2010.09.013 · DOI · Paper page
  24. Johnson, 2000, Perfusion abnormalities in prodromal AD, Neurobiol Aging., 21, 289, 10.1016/S0197-4580(00)00137-8 · DOI
  25. De la Torre, 2002, Vascular basis of Alzheimer's pathogenesis, Ann N Y Acad Sci., 977, 196, 10.1111/j.1749-6632.2002.tb04817.x · DOI · Paper page
  26. Zlokovic, 2005, Neurovascular mechanisms of Alzheimer's neurodegeneration, Trends Neurosci., 28, 202, 10.1016/j.tins.2005.02.001 · DOI · Paper page
  27. Marshall, 2006, Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels, Brain Res., 1099, 18, 10.1016/j.brainres.2006.05.008 · DOI
  28. Kelleher, 2013, Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?, Am J Cardiovasc Dis., 3, 197
  29. Wakita, 1992, Regional accumulation of amyloid beta/A4 protein precursor in the gerbil brain following transient cerebral ischemia, Neurosci Lett., 146, 135, 10.1016/0304-3940(92)90061-B · DOI
  30. Austin, 2010, Endothelial nitric oxide modulates expression and processing of amyloid precursor protein, Circ Res., 107, 1498, 10.1161/CIRCRESAHA.110.233080 · DOI · Paper page
  31. Zhao, 2011, The contribution of activated astrocytes to Abeta production: Implications for Alzheimer's disease pathogenesis, J Neuroinflammation., 8, 150, 10.1186/1742-2094-8-150 · DOI · Paper page
  32. Li, 2009, Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier, J Immunol., 182, 5778, 10.4049/jimmunol.0803013 · DOI · Paper page
  33. Galimberti, 2011, Disease-modifying treatments for Alzheimer's disease, Ther Adv Neurol Disord., 4, 203, 10.1177/1756285611404470 · DOI · Paper page
  34. Hayden, 2007, Does NSAID use modify cognitive trajectories in the elderly? The Cache County study, Neurology., 69, 275, 10.1212/01.wnl.0000265223.25679.2a · DOI · Paper page
  35. Pasinetti, 2002, From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: The role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia, J Alzheimers Dis., 4, 435, 10.3233/JAD-2002-4510 · DOI · Paper page
  36. Simons, 2002, Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial, Ann Neurol., 52, 346, 10.1002/ana.10292 · DOI · Paper page
  37. Sano, 2011, A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease, Neurology., 77, 556, 10.1212/WNL.0b013e318228bf11 · DOI · Paper page
  38. Shinohara, 2010, Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance, J Biol Chem., 285, 22091, 10.1074/jbc.M110.102277 · DOI · Paper page
  39. Li, 2006, Simvastatin enhances learning and memory independent of amyloid load in mice, Ann Neurol., 60, 729, 10.1002/ana.21053 · DOI · Paper page
  40. Wanamaker, 2015, Cholesterol, statins, and dementia: What the cardiologist should know, Clin Cardiol., 38, 243, 10.1002/clc.22361 · DOI · Paper page
  41. Yasar, 2013, Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo evaluation of memory study, Neurology., 81, 896, 10.1212/WNL.0b013e3182a35228 · DOI · Paper page
  42. Ashby, 2013, Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease, Expert Opin Investig Drugs., 22, 1229, 10.1517/13543784.2013.812631 · DOI · Paper page
  43. Zlokovic, 2008, New therapeutic targets in the neurovascular pathway in Alzheimer's disease, Neurotherapeutics., 5, 409, 10.1016/j.nurt.2008.05.011 · DOI · Paper page
  44. Hong-Qi, 2012, Current advances in the treatment of Alzheimer's disease: Focused on considerations targeting Aβ and tau, Transl Neurodegener., 1, 21, 10.1186/2047-9158-1-21 · DOI
  45. Galasko, 2014, Clinical trial of an inhibitor of RAGE-abeta interactions in Alzheimer disease, Neurology., 82, 1536, 10.1212/WNL.0000000000000364 · DOI · Paper page

Cited by

See all 70

Metadata

Authors
Rius-Pérez, S., Tormos, A. M., Pérez, S., & Taléns-Visconti, R.
Venue
Neurología
Publisher
Elsevier BV
Published
2018-03
Volume
33
Issue
2
Pages
112-120
ISSN
0213-4853 (ISSN-L)
OpenAlex
W2588435967
Cited by
70
References
37
FWCI
1.51
Type
journal article
Language
es
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.